What is the primary therapeutic goal of using leukotriene receptor antagonists like Montelukast?

Leukotriene receptor antagonists, such as Montelukast, are primarily used to inhibit inflammation, particularly in the context of respiratory conditions like asthma and allergic rhinitis. These medications work by blocking the action of leukotrienes, which are inflammatory mediators produced by the body in response to allergens or irritants. By inhibiting the receptors that leukotrienes bind to, Montelukast reduces airway inflammation, bronchoconstriction, and mucus overproduction. This leads to improved breathing and decreased symptoms in individuals suffering from asthma or allergic reactions.

The other options do not align with the primary therapeutic function of leukotriene receptor antagonists. Enhancing mucus secretion, promoting vasoconstriction, or stimulating cough reflexes are not the intended effects of these medications and do not describe their mechanism of action or therapeutic objectives. Thus, the goal of using medications like Montelukast centers on reducing inflammation to provide relief from related respiratory symptoms.